Insmed. has been granted a patent for a method to treat lupus nephritis using specific compounds that inhibit dipeptidyl peptidase 1 (DPP1) activity. The key compound involved is INS1007, a derivative of (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide. GlobalData’s report on Insmed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Insmed, Peptide pharmacophores was a key innovation area identified from patents. Insmed's grant share as of June 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Treating lupus nephritis with specific oxazepane compounds
The granted patent US11998553B2 outlines a method for treating lupus nephritis (LN) in patients through the administration of a pharmaceutical composition containing a specific compound, referred to as formula (I), or its pharmaceutically acceptable salts. The claims detail various structural characteristics of the compound, including specific substituents and configurations that define its chemical structure. Notably, the patent includes a range of compounds that fall under this formula, emphasizing their potential therapeutic applications in managing LN.
The treatment method encompasses several therapeutic objectives, such as reducing serum creatinine levels, decreasing active urinary sediment and casts, and achieving a reduction in urinary protein to creatinine ratio (UPCR). The claims also specify that the treatment may lead to a complete or partial renal response in patients. Additionally, the method allows for the co-administration of other active agents, including corticosteroids and immunosuppressants like mycophenolate mofetil or azathioprine, to enhance treatment efficacy. The patent highlights the versatility of the compounds and their potential to improve clinical outcomes for patients suffering from lupus nephritis.
To know more about GlobalData’s detailed insights on Insmed, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
